Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of IBI343 versus investigator's choice in previously treated CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
jRCT2031240503Phase 3Active, not recruiting
- Sponsor
- Fortvita Biologics
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of arcotatug tavatecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Fortvita Biologics. Started Dec 2024; status: active, not recruiting.
02
Drugs
arcotatug tavatecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031240503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240503.